Identifying the genes involved in Alzheimer’s disease and related dementias is of course no easy task. From among the thousands of gene candidates in the human genome, we need to determine which are involved in onset and progression, and which increase risk or offer protection.
A double-sided antibody targets enzyme to reduce levels of harmful amyloid-β protein in monkeys.
A new study published in the British Medical Journal finds that anti-anxiety drugs may increase the risk of Alzheimer’s.
The drugs have been associated with short-term cognitive impairment, but the connection to Alzheimer’s has been less clear. Now, the new study finds a convincing, and apparently strong, link between benzodiazepines and Alzheimer’s disease.
Epidemiologic evidences support that habitual caffeine intake prevents memory decline during aging and reduces the risk to develop Alzheimer’s disease. So far, experimental studies addressed the impact of caffeine in models mimicking the amyloid pathology of AD. However, in vivo effects of caffeine in a model of AD-like tauopathy remain unknown.
Dr. Neil Buckholtz of the NIA discusses ADNI in a summary of the recent presentations at the AAIC in Copenhagen and other Alzheimer’s research news.
From early morning to late evening, at symposium and plenary sessions, during poster sessions and coffee breaks, at add-on meetings and consortium sessions, some 4,300 investigators from 75 different countries shared recent findings and explored ways to overcome the challenges of finding ways to treat or prevent this complex disease.
Mayo Clinic researchers have demonstrated in a mouse model that they can move small-molecule drugs through the blood-brain barrier.
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications.
Exercise may help to keep the brain active in people with an increased risk of developing Alzheimer’s disease, according to a new study conducted by the Cleveland Clinic.
The findings suggest that even moderate amounts of physical activity may help to slow the progression of Alzheimer’s.
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer’s disease involving the so-called retromer protein complex.
Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer’s.
Incisive article from the NIA on challenges and new strategies for patient recruitment into AD clinical trials.
In this article we explore recruitment issues, including those unique to Alzheimer’s studies, and we suggest concrete steps such as establishing a structured consortium linking all of the registries of Alzheimer’s trials and establishing new partnerships with community and local organizations that can build trust and understanding among patients, caregivers, and providers.